Published in Clin Chem on April 24, 2009
Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation (2002) 2.73
Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation (2014) 2.65
Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol (2007) 2.56
High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ Res (2012) 2.26
High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol (2012) 2.24
[Corrected QT interval prolongation: a new predictor of cardiovascular risk in patients with non-ST-elevation acute coronary syndrome]. Rev Esp Cardiol (2008) 2.06
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol (2004) 2.00
Comparative study of ambient air particles in patients hospitalized for heart failure and acute coronary syndrome. Rev Esp Cardiol (2011) 1.97
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis (2008) 1.76
Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation (2003) 1.68
Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis (2011) 1.63
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J (2005) 1.58
Cystatin C and cardiovascular risk. Clin Chem (2009) 1.57
Pharmacological treatment of chronic stable angina pectoris. Clin Med (2013) 1.51
Fear of dying and inflammation following acute coronary syndrome. Eur Heart J (2011) 1.50
Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. Eur Heart J (2008) 1.48
New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions? JACC Cardiovasc Interv (2010) 1.46
Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation (2004) 1.45
Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res (2007) 1.43
Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X). Cardiovasc Drugs Ther (2012) 1.43
Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res (2005) 1.40
On-site immediate removal of intraortic balloon pump after high-risk percutaneous intervention with a 6 F closure suture device with the "preclosure" technique. Catheter Cardiovasc Interv (2007) 1.39
Prostate-specific antigen kallikrein is not a marker of non-ST elevation acute coronary syndrome. Int J Cardiol (2011) 1.39
Annual summary 2010: bibliometric data, activities, and new production of the journal. Rev Esp Cardiol (2010) 1.39
Unplanned redundant publication: a consequence of too many cardiovascular journals? EuroIntervention (2010) 1.39
Are prostate-specific antigen levels predictors of acute coronary syndrome or atrial fibrillation? Int J Cardiol (2012) 1.38
C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J (2004) 1.35
C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol (2003) 1.24
Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J (2003) 1.23
Neurocognitive function and cerebral emboli: randomized study of on-pump versus off-pump coronary artery bypass surgery. Ann Thorac Surg (2007) 1.18
Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ (2006) 1.15
Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation (2004) 1.14
Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol (2004) 1.09
Intracoronary abciximab and local anti-inflammatory effects. Int J Cardiol (2013) 1.08
Low frequency of embolic protection devices in saphenous vein intervention: a matter of lack of conviction? Catheter Cardiovasc Interv (2013) 1.07
Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur Heart J (2012) 1.07
Transcatheter Aortic Valve Replacement: Still in the Way of Learning. J Invasive Cardiol (2016) 1.06
Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis (2011) 1.05
The importance of echocardiography in transcatheter aortic valve implantation: TAVI: a multimodality approach. Echocardiography (2014) 1.05
Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations. Atherosclerosis (2009) 1.04
Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis (2004) 1.04
Pulse pressure and progression of chronic kidney disease. J Nephrol (2010) 1.03
Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med (2008) 1.02
Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol (2005) 1.02
Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol (2006) 1.01
A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovasc Res (2008) 0.98
Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging (2013) 0.97
Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J (2005) 0.97
Epidemiology of the diabetic heart. Coron Artery Dis (2005) 0.97
Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol (2003) 0.97
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation (2004) 0.96
Myocardial infarction in the elderly. Aging Dis (2010) 0.96
Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis (2006) 0.96
CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res (2008) 0.95
Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem (2004) 0.93
Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol (2005) 0.93
Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol (2011) 0.92
Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis (2008) 0.91
Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol (2005) 0.90
Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol (2004) 0.90
Neutrophil count and infarct size in patients with acute myocardial infarction. Int J Cardiol (2004) 0.90
Atherosclerotic plaque regression: fact or fiction? Cardiovasc Drugs Ther (2010) 0.89
Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis (2009) 0.89
Pseudoaneurysm complicating aortic coarctation in a pregnant woman. Int J Cardiol (2004) 0.88
Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis (2007) 0.88
Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: evidence for an association to haplogroup H. Mitochondrion (2010) 0.88
Atrioventricular conduction disturbance characterization in transcatheter aortic valve implantation with the CoreValve prosthesis. Circ Cardiovasc Interv (2011) 0.87
Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis (2005) 0.87
S100 protein and its relation to cerebral microemboli in on-pump and off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg (2004) 0.87
C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it? Eur Heart J (2009) 0.86
Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. Int J Cardiol (2010) 0.85
N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol (2005) 0.85
Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol (2010) 0.85
Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels (2008) 0.85
Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol (2004) 0.85
A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. Int J Cardiol (2005) 0.84
Effect of direct-current cardioversion on ischemia-modified albumin levels in patients with atrial fibrillation. Am J Cardiol (2004) 0.84
The Who, What, Why, When, How and Where of Vasospastic Angina. Circ J (2015) 0.84
Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice? Drug News Perspect (2009) 0.83
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs (2006) 0.83
Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Int J Cardiol (2012) 0.83
Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect? Cardiovasc Drugs Ther (2009) 0.83
Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale. Cardiovasc Drugs Ther (2009) 0.83
Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol (2006) 0.82